HHS proposal would expand clinical trial data disclosure requirements

 

The Department of Health & Human Services has released a proposed rule that would require companies to report summary results for drugs and devices that are never approved and not just for products that reach the marketplace, reports the American Association for the Advancement of Science.

The proposed regulation would ensure that summary results for drugs that fail in trials or dropped for other reasons are made public in ClinicalTrials.gov.

Read more below:

 

 

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”